Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5748MR)

This product GTTS-WQ5748MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5748MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8303MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ298MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ8090MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ11645MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ7262MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13746MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ10051MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ2100MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW